Three-dimensional quantitative structure-activity relationship analysis of cytochromes P450: Effect of incorporating higher-affinity ligands and potential new applications

Drug Metabolism and Disposition

Volumn 33, Issue 7, 2005, Pages 873-878

  Locuson, Charles W ^a,c   Wahlstrom, Jan L ^b,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d Pharmacokinetics Dynamics and Metabolism Department   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BARBITURIC ACID DERIVATIVE; BENZBROMARONE; CLOZAPINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DAPSONE; DEXTROMETHORPHAN; DIAZEPAM; DICLOFENAC; FLURBIPROFEN; HEXOBARBITAL; HYDANTOIN DERIVATIVE; IBUPROFEN; ISOXICAM; MEPHENYTOIN; MESTRANOL; MIDAZOLAM; NANOPARTICLE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENACETIN; PHENOBARBITAL; PHENYTOIN; SULFAPHENAZOLE; SULFONAMIDE; TENOXICAM; TESTOSTERONE; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

BINDING AFFINITY; DRUG BINDING SITE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ANALYSIS; ENZYME BINDING; HUMAN; MOLECULAR MODEL; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SHORT SURVEY; SUBSTITUTION REACTION; THREE DIMENSIONAL IMAGING;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; LIGANDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 22344436138     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.004325     Document Type: Short Survey

References (20)

1. Balakin KV, Ekins S, Bugrim A, Ivanenkov YA, Korolev D, Nikolsky YV, Skorenko AV, Ivashchenko AA, Savchuk NP, and Nikolskaya T (2004) Kohonen maps for prediction of binding to human cytochrome P450 3A4. Drug Metab Dispos 32:1183-1189.
2. Dickmann LJ, Locuson CW, Jones JP, and Rettie AE (2004) Differential roles of Arg97, Asp293 and Arg108 in enzyme stability and substrate specificity of CYP2C9. Mol Pharmacol 65:842-850.
3. Egnell AC, Eriksson C, Albertson N, Houston B, and Boyer S (2003) Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther 307:878-887.
4. Ekins S, de Groot MJ, and Jones JP (2001) Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab Dispos 29:936-944.
5. Evers A, Gohlke H, and Klebe G (2003) Ligand-supported homology modelling of protein binding-sites using knowledge-based potentials. J Mol Biol 334:327-345.
6. Kemp CA, Flanagan JU, van Eldik AJ, Marechal JD, Wolf CR, Roberts GC, Paine MJ, and Sutcliffe MJ (2004) Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition. J Med Chem 47:5340-5346.
7. Locuson CW, Rock DA, and Jones JP (2004a) Quantitative binding models for CYP2C9 based on benzbromarone analogues. Biochemistry 43:6948-6958.
8. Locuson CW, Suzuki H, Rettie AE, and Jones JP (2004b) Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors. J Med Chem 47:6768-6776.
9. Locuson CW, Wahlstrom JL, Rock DA, Rock DA, and Jones JP (2003) A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives. Drug Metab Dispos 31:967-971.
10. Martin-Biosca Y, Molero-Monfort M, Sagrado S, Villanueva-Camanas RM, and Medina-Hernandez MJ (2000) Development of predictive retention-activity relationship models of barbiturates by micellar liquid chromatography. Quant Struct-Act Relat 19:247-256.
11. Meunier B, de Visser SP, and Shaik S (2004) Mechanism of oxidation reactions catalyzed by cytochrome P450 enzymes. Chem Rev 104:3947-3980.
12. Rao S, Aoyama R, Schrag M, Trager WF, Rettie A, and Jones JP (2000) A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions. J Med Chem 43:2789-2796.
13. Shimodaira H, Takahashi K, Kano K, Matsumoto Y, Uchida Y, and Kudo T (1996) Enhancement of anticoagulant action by warfarin-benzbromarone interaction. J Clin Pharmacol 36:168-174.
14. Sutherland JJ, O'Brien LA, and Weaver DF (2004) A comparison of methods for modeling quantitative structure-activity relationships. J Med Chem 47:5541-5554.
15. Suzuki H, Kneller MB, Haining RL, Trager WF, and Rettie AE (2002) (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. Drug Metab Dispos 30:235-239.
16. Suzuki H, Kneller MB, Rock DA, Jones JP, Trager WF, and Rettie AE (2004) Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors. Arch Biochem Biophys 429:1-15.
17. Takahashi H, Sato T, Shimoyama Y, Shioda N, Shimizu T, Kubo S, Tamura N, Tainaka H, Yasumori T, and Echizen H (1999) Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin Pharmacol Ther 66:569-581.
18. Venhorst J, ter Laak AM, Commandeur JN, Funae Y, Hiroi T, and Vermeulen NP (2003) Homology modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational rationalization of experimental ligand-binding specificities. J Med Chem 46:74-86.
19. Wester MR, Yano JK, Schoch GA, Yang C, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J Biol Chem 279:35630-35637.
20. Williams PA, Cosme J, Ward A, Angove HC, Matak VD, and Jhoti H (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature (Lond) 424:464-468.